The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
2-(4-(1-(4-cyanophenyl)-3-methyl-4-nitro-1H-pyrazol-5-yloxy)phenyl)-1H-benzo[d]imidazole-5-carboxylic acid ID: ALA4100980
PubChem CID: 137658886
Max Phase: Preclinical
Molecular Formula: C25H16N6O5
Molecular Weight: 480.44
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: Cc1nn(-c2ccc(C#N)cc2)c(Oc2ccc(-c3nc4cc(C(=O)O)ccc4[nH]3)cc2)c1[N+](=O)[O-]
Standard InChI: InChI=1S/C25H16N6O5/c1-14-22(31(34)35)24(30(29-14)18-7-2-15(13-26)3-8-18)36-19-9-4-16(5-10-19)23-27-20-11-6-17(25(32)33)12-21(20)28-23/h2-12H,1H3,(H,27,28)(H,32,33)
Standard InChI Key: UVJAHTQJJBTJDW-UHFFFAOYSA-N
Molfile:
RDKit 2D
36 40 0 0 0 0 0 0 0 0999 V2000
37.8040 -9.9590 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.8029 -10.7785 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.5109 -11.1875 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.5091 -9.5501 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.2177 -9.9554 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.2225 -10.7740 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.0026 -11.0224 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
40.4799 -10.3573 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.9948 -9.6979 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
41.2951 -10.3520 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.7073 -11.0589 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.5237 -11.0544 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.9289 -10.3438 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.5118 -9.6362 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.6967 -9.6441 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.7461 -10.3379 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
44.1496 -9.6273 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
44.9606 -9.5333 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
45.1248 -8.7327 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
44.4141 -8.3292 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.8108 -8.8805 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
45.5128 -10.1356 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
45.2635 -10.9115 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
45.8150 -11.5136 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
46.6137 -11.3368 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
46.8580 -10.5526 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
46.3049 -9.9539 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.0069 -8.7140 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
42.4645 -9.3252 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
42.7488 -7.9386 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
44.3227 -7.5171 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.0962 -9.5505 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.0960 -8.7333 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
36.3886 -9.9593 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
47.1682 -11.9360 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
47.7212 -12.5376 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 1 0
8 9 2 0
9 5 1 0
10 11 2 0
11 12 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 10 1 0
8 10 1 0
13 16 1 0
16 17 1 0
17 18 1 0
18 19 1 0
19 20 2 0
20 21 1 0
21 17 2 0
18 22 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 26 1 0
26 27 2 0
27 22 1 0
28 29 2 0
28 30 1 0
21 28 1 0
20 31 1 0
1 32 1 0
32 33 2 0
32 34 1 0
35 36 3 0
25 35 1 0
M CHG 2 28 1 30 -1
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 480.44Molecular Weight (Monoisotopic): 480.1182AlogP: 4.99#Rotatable Bonds: 6Polar Surface Area: 159.96Molecular Species: ACIDHBA: 8HBD: 2#RO5 Violations: ┄HBA (Lipinski): 11HBD (Lipinski): 2#RO5 Violations (Lipinski): 1CX Acidic pKa: 2.16CX Basic pKa: 5.47CX LogP: 3.08CX LogD: 1.39Aromatic Rings: 5Heavy Atoms: 36QED Weighted: 0.25Np Likeness Score: -1.54
References 1. Galal SA, Abdelsamie AS, Shouman SA, Attia YM, Ali HI, Tabll A, El-Shenawy R, El Abd YS, Ali MM, Mahmoud AE, Abdel-Halim AH, Fyiad AA, Girgis AS, El-Diwani HI.. (2017) Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs., 134 [PMID:28433679 ] [10.1016/j.ejmech.2017.03.090 ]